DE60001623T2 - Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel - Google Patents

Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel

Info

Publication number
DE60001623T2
DE60001623T2 DE60001623T DE60001623T DE60001623T2 DE 60001623 T2 DE60001623 T2 DE 60001623T2 DE 60001623 T DE60001623 T DE 60001623T DE 60001623 T DE60001623 T DE 60001623T DE 60001623 T2 DE60001623 T2 DE 60001623T2
Authority
DE
Germany
Prior art keywords
heteroaryl
halo
sulfamoyl
analgesic
inflammatory agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60001623T
Other languages
English (en)
Other versions
DE60001623D1 (de
Inventor
Kazuo Ando
Kiyoshi Kawamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60001623D1 publication Critical patent/DE60001623D1/de
Application granted granted Critical
Publication of DE60001623T2 publication Critical patent/DE60001623T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
DE60001623T 1999-12-03 2000-11-24 Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel Expired - Fee Related DE60001623T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16888999P 1999-12-03 1999-12-03

Publications (2)

Publication Number Publication Date
DE60001623D1 DE60001623D1 (de) 2003-04-17
DE60001623T2 true DE60001623T2 (de) 2003-12-18

Family

ID=22613376

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60001623T Expired - Fee Related DE60001623T2 (de) 1999-12-03 2000-11-24 Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel

Country Status (11)

Country Link
US (2) US6603008B1 (de)
EP (1) EP1104760B1 (de)
JP (2) JP3338027B2 (de)
AT (1) ATE234299T1 (de)
BR (1) BR0005703A (de)
CA (1) CA2327385A1 (de)
DE (1) DE60001623T2 (de)
DK (1) DK1104760T3 (de)
ES (1) ES2193921T3 (de)
MX (1) MXPA00011844A (de)
PT (1) PT1104760E (de)

Families Citing this family (350)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
ES2240661T3 (es) 2001-07-05 2005-10-16 Pfizer Products Inc. Sulfonil-heteroaril-triazoles como agentes antiinflamatorios y analgesicos.
DE10135027A1 (de) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
JP2005515171A (ja) 2001-11-02 2005-05-26 ファイザー・プロダクツ・インク ５−ヘテロ原子含有ピラゾールの効率的な合成法
WO2003037335A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
WO2003037351A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
WO2003037330A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
WO2003037352A1 (en) * 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
SG128438A1 (en) 2002-03-15 2007-01-30 Sumitomo Chemical Co Polymer compound and polymer light emitting deviceusing the same
DE60305053T2 (de) * 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
JP2004326857A (ja) 2003-04-22 2004-11-18 Sony Corp 光磁気ディスクおよびその記録再生方法
WO2005041885A2 (en) * 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
EP1934201A1 (de) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterierte hemmer von gastrischer h+, k+-atpase mit verstärkten therapeutischen eigenschaften
PT1954669E (pt) * 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
PL1991522T3 (pl) * 2006-02-17 2017-07-31 Ratiopharm Gmbh Deuterowane pochodne katecholaminy i leki zawierające te związki
CA2646229A1 (en) * 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
CA2653262A1 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
BRPI0711491A2 (pt) * 2006-06-05 2012-07-10 Auspex Pharmaceuticals Inc composição, método de tratamento de um mamìfero que sofre uma doença ou de uma condição que envolve um receptor de benzodiazepina e composição farmacêutica"
CA2660659A1 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
WO2008024439A2 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-aminoquinazoline derivatives and methods of use thereof
EP2063893A2 (de) * 2006-08-24 2009-06-03 Concert Pharmaceuticals Inc. 3,4-dihydro-2(1h)-chinolinon und 2(1h)-chinolinon-derivate
CA2666149A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
AU2007329728A1 (en) * 2006-10-20 2008-06-12 Concert Pharmaceuticals Inc. 3-(dihydro-1H-pyrazolo (4,3-d) pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20080280927A1 (en) * 2006-10-20 2008-11-13 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090270425A1 (en) * 2006-10-20 2009-10-29 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090197899A1 (en) * 2006-10-20 2009-08-06 Concert Pharmaceuticals Inc. 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
JP5302200B2 (ja) * 2006-10-23 2013-10-02 コンサート ファーマシューティカルズ インコーポレイテッド オキサゾリジノン誘導体および使用方法
US8796267B2 (en) * 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US7932235B2 (en) * 2006-11-17 2011-04-26 Concert Pharmaceuticals, Inc. Triazolyl tropane derivatives
US20080146573A1 (en) * 2006-12-04 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted oxzolidinones
US20080167312A1 (en) * 2006-12-08 2008-07-10 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted allylamines
US20100260674A1 (en) * 2006-12-15 2010-10-14 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
WO2008076949A2 (en) * 2006-12-15 2008-06-26 Concert Pharmaceuticals Inc. Quinazoline derivatives and methods of treatment
US20090325976A1 (en) * 2006-12-21 2009-12-31 Concert Pharmaceuticals Inc. Prostacyclin derivatives
US8071596B2 (en) * 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US20080262006A1 (en) * 2007-02-02 2008-10-23 Harbeson Scott L Selective endothelin type-a antagonists
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
WO2008106125A2 (en) * 2007-02-26 2008-09-04 Concert Pharmaceuticals, Inc. Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
US7943620B2 (en) * 2007-03-07 2011-05-17 Concert Pharmaceuticals, Inc. Anti-anginal compounds
HUE031070T2 (en) * 2007-03-15 2017-06-28 Auspex Pharmaceuticals Inc Deuterated d9-venlafaxine
US8759383B2 (en) * 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
US20080261926A1 (en) * 2007-04-02 2008-10-23 Liu Julie F Pharmaceutical Calcimimetics
CN101679244B (zh) 2007-04-11 2014-01-01 橘生药品工业株式会社 5元杂环衍生物及其医药用途
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
EP2152689B1 (de) * 2007-04-25 2013-01-02 Concert Pharmaceuticals Inc. Analoga von cilostazol
US8349817B2 (en) * 2007-04-25 2013-01-08 Concert Pharmaceuticals, Inc. Analogues of cilostazol
CA3056205C (en) 2007-05-01 2023-09-26 Concert Pharmaceuticals Inc. Morphinan compounds
MX2009011958A (es) 2007-05-01 2010-06-30 Concert Pharmaceuticals Inc Compuestos de morfina.
JP4642134B2 (ja) * 2007-05-01 2011-03-02 コンサート ファーマシューティカルズ インコーポレイテッド ナフチル（エチル）アセトアミド
WO2008141033A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals Inc. Substituted naphthalenes
US7820666B2 (en) * 2007-05-08 2010-10-26 Concert Pharmaceuticals, Inc. Tetrahydrotriazolopyrazine derivatives and uses thereof
US20080306151A1 (en) * 2007-06-11 2008-12-11 Protia, Llc Deuterium-enriched fenofibrate
KR101185899B1 (ko) 2007-06-12 2012-09-27 콘서트 파마슈티컬즈, 인크. 아자펩티드 유도체
WO2008157240A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090005366A1 (en) * 2007-06-19 2009-01-01 Protia, Llc Deuterium-enriched olanzapine
US20080319004A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched clopidogrel
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
US7915309B2 (en) * 2007-06-20 2011-03-29 Protia, Llc Deuterium-enriched oseltamivir
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
US20080318915A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched fluticasone propionate
US7687509B2 (en) * 2007-07-09 2010-03-30 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives
EP2170825A2 (de) * 2007-07-30 2010-04-07 Auspex Pharmaceuticals, Inc. Substituierte indole
EP2190841B1 (de) * 2007-08-14 2013-05-15 Concert Pharmaceuticals Inc. Substituierte oxazolidinonderivate
US20090062385A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched fesoterodine
US20090062305A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched cetirizine
US20090062561A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched latanoprost
US20090062399A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sertraline
US20090062283A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched linezolid
US20090062299A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched doxazosin
US20090062374A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched lasofoxifene
US20090062316A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched pelitrexol
US20090062393A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched pregabalin
US20090069352A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched clazosentan
US20090069357A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched iclaprim
US20090069413A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched olopatadine
US20090069375A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched miglustat
US20090069410A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched paclitaxel
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090069339A1 (en) * 2007-09-11 2009-03-12 Protia, Llc Deuterium-enriched ciprofloxacin
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
US20090076165A1 (en) * 2007-09-12 2009-03-19 Protia, Llc Deuterium-enriched memantine
US7994194B2 (en) * 2007-09-12 2011-08-09 Concert Pharmaceuticals, Inc. 4-oxoquinoline derivatives
US8288414B2 (en) * 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
US20090075965A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched amoxicilin
US20090076112A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched eltrombopag
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090076118A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched saxagliptin
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
WO2009035652A1 (en) * 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US7919516B2 (en) * 2007-09-13 2011-04-05 Protia, Llc Deuterium-enriched ondansetron
US20090076161A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched bupropion
US20090076038A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched entecavir
US20090076034A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched bms-690514
US20090076102A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched muraglitazar
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
US20090076148A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched pravastatin
US20090075991A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched efavirenz
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
US20090076025A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched dasatinib
US20090076164A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched tapentadol
US20090076040A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched valganciclovir
US20090076138A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched darunavir
US20090076028A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched itraconazole
US20090076264A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched rivaroxaban
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
US20090075944A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ibandronate
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
US20090076163A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched dapoxetine
US20090075953A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ed-71
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US20090076027A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20090076126A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched enalapril
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
US20090076153A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched tigecycline
US20090076134A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched simvastatin
US20090076154A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched vorinostat
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090075947A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched fospropofol
US20090076167A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched tramiprosate
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090076011A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched tirapazamine
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
US20090076159A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
US20090075997A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched satavaptan
US20090082312A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched zoledronic acid
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
US20090082382A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched naltrexone
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
US20090082380A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched rosuvastatin
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
US20090082323A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched fulvestrant
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
US20090082376A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched alogliptin
US20090082364A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levocedtirizine
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US20090082318A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched mometasone
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
US20090082363A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched posaconazole
US20090082335A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched oxcarbazepine
US20090082459A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched guanfacine
US20090082432A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched ramelteon
US20090143363A1 (en) * 2007-10-15 2009-06-04 Concert Pharmaceuticals, Inc. Deuterated lorcaserin
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009054964A1 (en) * 2007-10-22 2009-04-30 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
US8592487B2 (en) * 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
US20090131363A1 (en) * 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
EP2217561A2 (de) * 2007-11-02 2010-08-18 Concert Pharmaceuticals, Inc. Deuteriertes fingolimod
JP2011503231A (ja) * 2007-11-20 2011-01-27 コンサート ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染処置のためのペプチド
EP2222166B9 (de) * 2007-12-10 2012-11-07 Concert Pharmaceuticals Inc. Heterocyclische kinasehemmer
US8084464B2 (en) * 2007-12-18 2011-12-27 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
US8609673B2 (en) * 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
EP2242493B1 (de) * 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Gefitinib-derivate
WO2009102707A2 (en) * 2008-02-11 2009-08-20 Auspex Pharmaceuticals, Inc. Substituted oxazaphosphorines
US20090209550A1 (en) * 2008-02-20 2009-08-20 Auspex Pharmaceuticals, Inc. Substituted triazolopyridines
JP5292413B2 (ja) * 2008-02-29 2013-09-18 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
US8637486B2 (en) * 2008-03-14 2014-01-28 Retrotope, Inc. Therapeutic substances that modulate genome methylation
CA2715036A1 (en) * 2008-03-14 2009-09-17 Retrotope, Inc. Therapies for cancer using isotopically substituted lysine
US20090269354A1 (en) * 2008-03-28 2009-10-29 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
JP2011518783A (ja) * 2008-04-09 2011-06-30 コンサート ファーマシューティカルズ インコーポレイテッド ３−（２−ヒドロキシ−５−メチルフェニル）−ｎ，ｎ−ジイソプロピル−３−フェニルプロピルアミンの誘導体およびその使用方法
US8168814B2 (en) * 2008-04-10 2012-05-01 New Mexico Highlands University Synthesis of phosphonic acid labeled compounds
WO2009128947A1 (en) * 2008-04-17 2009-10-22 Concert Pharmaceuticals, Inc. Piperazine derivatives
WO2009145852A1 (en) * 2008-04-17 2009-12-03 Concert Pharmaceuticals, Inc. Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
US20100120786A1 (en) * 2008-04-17 2010-05-13 Concert Pharmaceuticals, Inc. Piperazine Derivatives
WO2009140225A2 (en) * 2008-05-13 2009-11-19 Auspex Pharmaceuticals, Inc. Anti-inflammatory and immunosuppresive glucocorticoid steroids
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
US8354557B2 (en) * 2008-06-17 2013-01-15 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
US20110294815A1 (en) * 2008-06-27 2011-12-01 Harbeson Scott L Prostacyclin analogs
US20100016365A1 (en) * 2008-07-17 2010-01-21 Auspex Pharmaceuticals, Inc. Substituted 4-amino-piperidines
WO2010011868A2 (en) * 2008-07-23 2010-01-28 Auspex Pharmaceuticals Pyridine sulfonamide modulators of endothelin-a-receptor
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
WO2010025407A1 (en) * 2008-08-29 2010-03-04 Concert Pharmaceuticals Inc. Substituted triazolo-pyridazine derivatives
US20100105755A1 (en) * 2008-09-12 2010-04-29 Auspex Pharmaceuticals, Inc. Substituted benzamide modulators of dopamine receptor
EP2334621A1 (de) * 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterierte 2-amino-3-hydroxypropansäurederivate
WO2010033270A1 (en) * 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
HUE038158T2 (hu) * 2008-09-18 2018-09-28 Auspex Pharmaceuticals Inc Deuterizált benzokinolizin származékok vezikuláris monoamin transzporter-2 inhibitorként
KR101716512B1 (ko) 2008-09-19 2017-03-14 콘서트 파마슈티컬즈, 인크. 모르피난 화합물
US20100087455A1 (en) * 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
US20100099701A1 (en) * 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
US20100113431A1 (en) * 2008-11-05 2010-05-06 Auspex Pharmaceuticals, Inc. N-methyl piperazine modulators of h1 receptor
WO2010054158A2 (en) * 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
WO2010056741A2 (en) * 2008-11-12 2010-05-20 Auspex Pharmaceuticals, Inc. Phenylacetic acid inhibitors of cyclooxygenase
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US20100137215A1 (en) * 2008-11-25 2010-06-03 Concert Pharmaceuticals Inc. Novel tetrahydro-1h-pyrido[4,3-b]indoles
US20110313004A1 (en) * 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20100143354A1 (en) * 2008-12-04 2010-06-10 Auspex Pharmaceuticals, Inc. Triazine dna modifiers
US20100144657A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
RU2528333C2 (ru) * 2008-12-23 2014-09-10 Аквилус Фармасьютикалз, Инк Соединения и способы лечения боли и других заболеваний
US20120053159A1 (en) * 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
US8263601B2 (en) * 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
WO2010107791A2 (en) 2009-03-17 2010-09-23 Concert Pharmaceuticals, Inc. Pyrazinoisoquinoline compounds
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
WO2010118291A2 (en) 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
CN102459270B (zh) 2009-04-20 2015-04-29 奥斯拜客斯制药有限公司 Janus激酶3的哌啶抑制剂
WO2010123999A2 (en) * 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
WO2010124046A1 (en) 2009-04-23 2010-10-28 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
US20100305173A1 (en) * 2009-04-30 2010-12-02 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
EP2434895A4 (de) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc Organische verbindungen
US8410082B2 (en) 2009-05-22 2013-04-02 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
WO2010144499A2 (en) * 2009-06-09 2010-12-16 Medolution Limited Urea derivatives as kinase inhibitors
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
US8586760B2 (en) 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
RS53357B (en) 2009-06-18 2014-10-31 Concert Pharmaceuticals Inc. ISOINDOLINE-1,3-DION DEUTERUM DERIVATIVES AS PDE4 AND TNF-ALPHA INHIBITORS
WO2011005520A1 (en) * 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20100325228A1 (en) * 2009-06-23 2010-12-23 Alon Novy Systems and methods for distributed activity management system
US20110015155A1 (en) * 2009-07-17 2011-01-20 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses
EP2456311A4 (de) * 2009-07-24 2013-01-23 Concert Pharmaceuticals Inc Substituierte imidazotriazine
ES2605625T3 (es) 2009-07-27 2017-03-15 Auspex Pharmaceuticals, Inc. Moduladores de ciclopropilo del receptor P2Y12
US8637524B2 (en) * 2009-07-28 2014-01-28 Auspex Pharmaceuticals, Inc Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2
US9512104B2 (en) 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8575348B2 (en) * 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8618116B2 (en) * 2009-08-03 2013-12-31 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
WO2011020044A1 (en) * 2009-08-14 2011-02-17 Concert Pharmaceuticals, Inc. Substituted triazolophthalazine derivatives
IN2012DN01642A (de) * 2009-09-02 2015-06-05 Concert Pharmaceuticals Inc
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011047315A1 (en) * 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
WO2011056511A2 (en) * 2009-10-26 2011-05-12 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
KR20120092142A (ko) * 2009-10-28 2012-08-20 애나디스 파마슈티칼스, 인코포레이티드 중수소화 5,6-다이하이드로-1ｈ-파이리딘-2-온 화합물
WO2011060363A2 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
WO2011063001A1 (en) * 2009-11-18 2011-05-26 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
BR112012012085A2 (pt) * 2009-11-21 2016-05-17 Hoffmann La Roche compostos antivirais heterocíclicos
US20110152303A1 (en) * 2009-12-18 2011-06-23 Glaxosmithkline Llc Chemical Compounds
US20110178180A1 (en) * 2010-01-18 2011-07-21 Kurt Nielsen Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof
US20110195066A1 (en) * 2010-02-05 2011-08-11 Auspex Pharmaceuticals, Inc. Quinoline inhibitors of tyrosine kinase
EP2539347A2 (de) * 2010-02-24 2013-01-02 Auspex Pharmaceuticals, Inc. Trimethoxyphenylhemmer von tyrosinkinase
JP2013521289A (ja) * 2010-03-01 2013-06-10 コンサート ファーマシューティカルズ インコーポレイテッド フルオロウラシル誘導体
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8513434B2 (en) * 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2011116066A1 (en) 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
MX2013002453A (es) * 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
CN102464652B (zh) * 2010-11-02 2013-08-28 北京欧博方医药科技有限公司 咪唑衍生物、制备方法及用途
US20130310396A1 (en) * 2011-01-19 2013-11-21 Hongwen Zhu Thiazolidine derivatives and their therapeutic use
JPWO2012102387A1 (ja) * 2011-01-27 2014-07-03 日産化学工業株式会社 ピラゾール誘導体及び有害生物防除剤
KR101976218B1 (ko) 2011-02-14 2019-05-07 콘서트 파마슈티컬즈, 인크. 4-히드록시부티르산 중수소화 유사체
ES2659763T3 (es) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2012122028A2 (en) 2011-03-04 2012-09-13 Concert Pharmaceuticals Inc. Pyrazinoisoquinoline compounds
US9018232B2 (en) 2011-03-08 2015-04-28 Auspex Pharmaceuticals, Inc. Substituted N-aryl pyridinones
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
DK2705013T3 (en) 2011-05-04 2016-07-18 Balance Therapeutics Inc Pentylenetetrazolderivater
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
JP6062432B2 (ja) * 2011-07-27 2017-01-18 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． プロテインキナーゼ阻害薬用スピロ環状分子
US8389723B1 (en) * 2011-08-24 2013-03-05 Glaxosmithkline Llc Deuterated benzene sulfonamide thiazole compounds
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
CN104114544A (zh) * 2012-02-08 2014-10-22 默克专利有限公司 用作卵泡刺激素受体激动剂的氘化噻唑烷酮类似物
JP2015512947A (ja) * 2012-04-13 2015-04-30 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
WO2013168013A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
US20150197525A1 (en) * 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
WO2014008417A1 (en) 2012-07-04 2014-01-09 Concert Pharmaceuticals, Inc. Deuterated vercirnon
ES2694202T3 (es) 2012-07-12 2018-12-19 Concert Pharmaceuticals, Inc. Idebenona deuterada
KR20150038486A (ko) 2012-07-30 2015-04-08 콘서트 파마슈티컬즈, 인크. 중수소화된 아이브루티닙
GB201214169D0 (en) 2012-08-08 2012-09-19 Biostatus Ltd New compounds and uses thereof
EP3492472A1 (de) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuteriertes baricitinib mit verbesserter metabolischer stabilität als jak1 und jak2 kinase inhibitor zur behandlung von rheumatoider arthritis
EP2888222A1 (de) * 2012-08-22 2015-07-01 Concert Pharmaceuticals Inc. Deuterierte 4-hydroxybuttersäureanaloga
WO2014039748A1 (en) * 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
CN116768882A (zh) 2012-09-18 2023-09-19 奥斯拜客斯制药有限公司 化合物、及其药物组合物及治疗方法
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9643950B2 (en) 2012-10-22 2017-05-09 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
CA2897814C (en) 2013-01-09 2022-06-21 Concert Pharmaceuticals, Inc. Deuterated momelotinib
WO2014110558A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
AU2014212586A1 (en) * 2013-01-31 2015-08-06 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of VMAT2
WO2014121036A1 (en) * 2013-02-01 2014-08-07 Deuterx, Llc 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
GB201302368D0 (en) * 2013-02-11 2013-03-27 Univ Bath Compound
EP2956141A4 (de) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc Neuartige verwendungen
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
US8946424B2 (en) * 2013-05-02 2015-02-03 The Regents Of The University Of Michigan Deuterated amlexanox
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
KR102391134B1 (ko) 2013-12-03 2022-04-28 오스펙스 파마슈티칼스, 인코포레이티드 벤조퀴놀린 화합물을 제조하는 방법
WO2015085132A1 (en) * 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
WO2015095713A1 (en) 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
MX2016009817A (es) * 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
CN104817559B (zh) * 2014-01-30 2021-05-25 苏州泽璟生物制药股份有限公司 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US20170014341A1 (en) 2014-04-04 2017-01-19 Lam Therapeutics, Inc. An Inhalable Rapamycin Formulation for Treating Age-Related Conditions
MX365969B (es) 2014-04-04 2019-06-21 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
EP3157926B1 (de) * 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organische verbindungen
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
EP3209330B1 (de) 2014-10-07 2022-02-23 AI Therapeutics, Inc. Inhalierbare sirolimus formulierung zur behandlung von pulmonaler hypertonie
EP3212656B1 (de) 2014-10-27 2019-06-05 Concert Pharmaceuticals Inc. Pyrimidinphosphonsäureester mit mindestens einem deuteriumatom
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US20190055235A1 (en) * 2014-12-17 2019-02-21 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
EP3250557A4 (de) 2015-01-29 2018-06-20 Signal Pharmaceuticals, LLC Isotopologe von 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
CN114796209A (zh) 2015-03-06 2022-07-29 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
US20180311258A1 (en) * 2015-04-10 2018-11-01 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10683305B2 (en) * 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
CN107698620A (zh) * 2015-06-23 2018-02-16 江苏天士力帝益药业有限公司 一种氘代噻吩并哌啶衍生物、制备方法及其应用
EP3301095B1 (de) * 2015-06-26 2019-12-04 Chongqing Dikang Erle Pharma Co. Ltd. Neuartige phosphodiesterase-typ-5-inhibitoren und anwendung davon
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
MA42954A (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals Europe Ltd Potentialisateurs cftr deutérés
MA43848A (fr) * 2015-10-21 2018-11-21 Neuform Pharmaceuticals Inc Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
DK3838274T3 (da) 2016-01-26 2024-01-22 Intra Cellular Therapies Inc Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-derivat til brug til behandling af cns-lidelser
US10214536B2 (en) 2016-01-29 2019-02-26 The Regents Of The University Of Michigan Amlexanox analogs
WO2017133360A1 (zh) * 2016-02-02 2017-08-10 深圳市塔吉瑞生物医药有限公司 一种甾体类化合物及包含该化合物的组合物及其用途
WO2017143038A1 (en) 2016-02-16 2017-08-24 Concert Pharmaceuticals, Inc. Deuterated gft-505
WO2017147159A1 (en) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
US10688097B2 (en) 2016-03-25 2020-06-23 Intra-Cellular Therapies, Inc. Organic compounds
EP3436083A4 (de) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Neuartige zusammensetzungen und verfahren
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
CN114805211A (zh) 2017-03-21 2022-07-29 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
EP3600325A4 (de) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. Neuartige zusammensetzungen und verfahren
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
MX2019013574A (es) * 2017-05-16 2019-12-18 Vertex Pharma Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
US20200368193A1 (en) 2017-11-22 2020-11-26 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
CN111479804B (zh) 2017-12-01 2023-12-22 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
CN111362949B (zh) * 2017-12-22 2021-12-21 深圳市塔吉瑞生物医药有限公司 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
JP7162915B2 (ja) 2018-01-23 2022-10-31 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾロ［１，５－ａ］ピリミジン系大環状化合物
WO2019152697A1 (en) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses
CN109970745B (zh) * 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
CA3103965A1 (en) * 2018-06-19 2019-12-26 Celecor Therapeutics, Inc. Deuterated ruc-4
JP7262843B2 (ja) * 2018-07-12 2023-04-24 深▲チェン▼市塔吉瑞生物医薬有限公司 ジアリールピラゾール化合物、該化合物を含む組成物およびその使用
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
US11851409B2 (en) * 2019-01-25 2023-12-26 Qingdao Jião Pharmaceutical Technology Co., Ltd Deuterated benzylaminopyrimidinedione derivatives and use thereof
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US20230150965A1 (en) * 2021-11-05 2023-05-18 Terran Biosciences, Inc. Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
DK0731795T3 (da) 1993-11-30 2000-05-15 Searle & Co Substituerede pyrazolylbenzensulfonamider til behandling af inflammation
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5401765A (en) 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
CA2195847A1 (en) 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
ATE232856T1 (de) 1994-12-21 2003-03-15 Merck Frosst Canada Inc Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
ATE212343T1 (de) 1995-10-30 2002-02-15 Merck Frosst Canada Inc 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.

Also Published As

Publication number Publication date
MXPA00011844A (es) 2002-08-20
DE60001623D1 (de) 2003-04-17
PT1104760E (pt) 2003-06-30
ATE234299T1 (de) 2003-03-15
CA2327385A1 (en) 2001-06-03
JP3338027B2 (ja) 2002-10-28
US20030144280A1 (en) 2003-07-31
ES2193921T3 (es) 2003-11-16
JP2001163883A (ja) 2001-06-19
US6603008B1 (en) 2003-08-05
BR0005703A (pt) 2001-07-31
EP1104760B1 (de) 2003-03-12
DK1104760T3 (da) 2003-06-30
JP2002284682A (ja) 2002-10-03
EP1104760A1 (de) 2001-06-06
US6951876B2 (en) 2005-10-04

Similar Documents

Publication Publication Date Title
DE60001623D1 (de) Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
ATE252576T1 (de) Heteroarylphenylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
HUP0203971A2 (hu) Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO953305D0 (no) Antranilsyrederivat
ATE223378T1 (de) Prolineamid-derivate
AU695045B2 (en) Heteroaromatic oxazole compounds and use thereof
DE60111205D1 (de) Triarylimidazol-derivate als cytokin-inhibitoren
DE69835877D1 (de) Trizyklische verbindungen
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DE69110219D1 (de) 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
EP1319658A4 (de) Imidazolderivate oder ihre salze
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
TH64776A (th) สารประกอบไพราโซล, องค์ประกอบทางเภสัชกรรมและวิธีการสำหรับการปรับ และ/หรือ การยับยั้งการออกฤทธิ์ erab/hadh2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee